It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Patients carrying autosomal dominant mutations in the histone/lysine acetyl transferases CBP or EP300 develop a neurodevelopmental disorder: Rubinstein-Taybi syndrome (RSTS). The biological pathways underlying these neurodevelopmental defects remain elusive. Here, we unravel the contribution of a stress-responsive pathway to RSTS. We characterize the structural and functional interaction between CBP/EP300 and heat-shock factor 2 (HSF2), a tuner of brain cortical development and major player in prenatal stress responses in the neocortex: CBP/EP300 acetylates HSF2, leading to the stabilization of the HSF2 protein. Consequently, RSTS patient-derived primary cells show decreased levels of HSF2 and HSF2-dependent alteration in their repertoire of molecular chaperones and stress response. Moreover, we unravel a CBP/EP300-HSF2-N-cadherin cascade that is also active in neurodevelopmental contexts, and show that its deregulation disturbs neuroepithelial integrity in 2D and 3D organoid models of cerebral development, generated from RSTS patient-derived iPSC cells, providing a molecular reading key for this complex pathology.
Rubinstein-Taybi syndrome (RSTS) is a neurodevelopmental disorder with unclear underlying mechanisms. Here, the authors unravel the contribution of a stress-responsive pathway to RSTS where impaired HSF2 acetylation, due to RSTS-associated CBP/EP300 mutations, alters the expression of neurodevelopmental players, in keeping with hallmarks of cell-cell adhesion defects.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details















1 Université de Paris, CNRS, Epigenetics and Cell Fate, Paris, France
2 Åbo Akademi University, Faculty of Science and Engineering, Cell Biology, Turku, Finland (GRID:grid.13797.3b) (ISNI:0000 0001 2235 8415); University of Turku and Åbo Akademi University, Turku Bioscience Centre, Turku, Finland (GRID:grid.1374.1) (ISNI:0000 0001 2097 1371)
3 Université de Paris, CNRS, Epigenetics and Cell Fate, Paris, France (GRID:grid.1374.1)
4 Université de Paris, CNRS, Unité de Biologie Fonctionnelle et Adaptative, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602)
5 Université de Paris, CNRS, Epigenetics and Cell Fate, Paris, France (GRID:grid.508487.6); Ksilink, Strasbourg, France (GRID:grid.508487.6)
6 Université de Paris, CNRS, Epigenetics and Cell Fate, Paris, France (GRID:grid.508487.6)
7 University of Liège, CHU Sart Tilman, Laboratory of Molecular Regulation of Neurogenesis, GIGA-Stem Cells and GIGA-Neurosciences, Interdisciplinary Cluster for Applied Genoproteomics (GIGA-R), Liège, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253)
8 Université de Nantes, CHU Nantes, Inserm, CNRS, SFR Santé, Nantes, France (GRID:grid.4817.a) (ISNI:0000 0001 2189 0784)
9 Laboratoire d’Excellence LipSTIC, INSERM, UMR1231, Dijon, France (GRID:grid.7429.8) (ISNI:0000000121866389); University of Bourgogne Franche-Comté, Dijon, France (GRID:grid.493090.7) (ISNI:0000 0004 4910 6615); Centre Georges-François Leclerc, Département d’Oncologie médicale, Dijon, France (GRID:grid.418037.9) (ISNI:0000 0004 0641 1257)
10 Université de Paris, CNRS, Epigenetics and Cell Fate, Paris, France (GRID:grid.418037.9)
11 CNRS, UMR 7592 Institut Jacques Monod, Paris, France (GRID:grid.4444.0) (ISNI:0000 0001 2112 9282)
12 Université de Paris, CNRS, Epigenetics and Cell Fate, Paris, France (GRID:grid.4444.0)
13 Åbo Akademi University, Faculty of Science and Engineering, Cell Biology, Turku, Finland (GRID:grid.13797.3b) (ISNI:0000 0001 2235 8415); University of Turku and Åbo Akademi University, Turku Bioscience Centre, Turku, Finland (GRID:grid.1374.1) (ISNI:0000 0001 2097 1371); KTH Royal Institute of Technology, Stockholm, Sweden (GRID:grid.5037.1) (ISNI:0000 0001 2158 1746)
14 Université de Paris, CNRS, Epigenetics and Cell Fate, Paris, France (GRID:grid.1374.1); Neuroscience Institute-CNR (IN-CNR), Milan, Italy (GRID:grid.418879.b) (ISNI:0000 0004 1758 9800)
15 University Hospital of Bordeaux, Bordeaux, France and INSERM U1211, University of Bordeaux, Department of Medical Genetics, Bordeaux, France (GRID:grid.42399.35) (ISNI:0000 0004 0593 7118)
16 Hopitaux Universitaires Paris-Sud, Service de Biochimie-pharmaco-toxicologie, Hôpital Bicêtre, Paris-Sud, France (GRID:grid.413784.d) (ISNI:0000 0001 2181 7253)
17 Université de Paris, INSERM, NeuroDiderot, Robert-Debré Hospital, Paris, France (GRID:grid.413784.d); AP-HP, Robert-Debré University Hospital, Genetics Department, Paris, France (GRID:grid.413235.2) (ISNI:0000 0004 1937 0589)
18 Université de Paris, INSERM, NeuroDiderot, Robert-Debré Hospital, Paris, France (GRID:grid.413235.2)
19 University of South Florida, Department of Cell Biology, Microbiology, and Molecular Biology, College of Arts and Sciences, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X)
20 Université de Paris, INSERM, NeuroDiderot, Robert-Debré Hospital, Paris, France (GRID:grid.508487.6)
21 Cambridge Biomedical, Campus, MRC Laboratory of Molecular Biology, Cambridge, UK (GRID:grid.42475.30) (ISNI:0000 0004 0605 769X)